SCHEMBL13518

SCHEMBL13518

CCCC(CC1CCCCC1)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.42
METAP2 P50579 1/20 0.40
EPHX1 P07099 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
LTA4H P09960 1/20 0.38
ATM Q13315 1/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSK P43235 1/20 0.38
REN P00797 1/20 0.38
ALOX5 P09917 1/20 0.38
CHRM1 P11229 1/20 0.38
AKR1A1 P14550 1/20 0.38
CHRM3 P20309 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6393775 0.91 CA1 (0.44) ALDH1A1KMT2ASMN1; SMN2CA1CA2
SCHEMBL9201 0.85 ATM (0.46) ALDH1A1KMT2AMETAP2EPHX1CA1
SCHEMBL5515416 0.84 SMN1; SMN2 (0.54) ALDH1A1KMT2ASMN1; SMN2METAP2LTA4H
SCHEMBL18050479 0.84 SMN1; SMN2 (0.54) ALDH1A1KMT2ASMN1; SMN2METAP2LTA4H
SCHEMBL9456 0.79 ALDH1A1 (0.49) ALDH1A1KMT2ASMN1; SMN2METAP2LTA4H
SCHEMBL7371371 0.79 ALDH1A1 (0.39) ALDH1A1KMT2AMETAP2EPHX1CTSL
SCHEMBL2188236 0.79 CA2 (0.53) ALDH1A1KMT2AMETAP2EPHX1CA1
SCHEMBL13500182 0.77 ALDH1A1 (0.47) ALDH1A1KMT2ASMN1; SMN2METAP2LTA4H
SCHEMBL23522253 0.76 ALDH1A1 (0.43) ALDH1A1KMT2ASMN1; SMN2METAP2LTA4H
SCHEMBL13499659 0.76 LTA4H (0.49) ALDH1A1KMT2ASMN1; SMN2METAP2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP ALDH1A1 1846/4885KMT2A 1441/4885SMN1; SMN2 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.